Miltefosine + Paromomycin

DRUG2 trials

Sponsors

Drugs for Neglected Diseases, Institute of Tropical Medicine, Belgium

Conditions

Cutaneous LeihmaniasisVisceral Leishmaniasis

Phase 3

Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

CompletedNCT01122771

Drugs for Neglected DiseasesVisceral Leishmaniasis

Start: 2010-05-31End: 2014-03-31Updated: 2016-01-21

Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)

Not yet recruitingNCT07463040

Institute of Tropical Medicine, BelgiumCutaneous Leihmaniasis

Start: 2027-01-01End: 2029-08-31Target: 900Updated: 2026-03-10

Related Papers

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh

PLoS neglected tropical diseases2017-05-3073 citations